v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Net revenue    
Total net revenue $ 348,116 $ 255,737
Cost and operating expenses    
Technology research and development 45,921 33,391
Research and development 48,237 35,874
Selling, general and administrative 212,594 154,627
Total cost and operating expenses 432,827 324,426
Loss from operations (84,711) (68,689)
Interest income 3,866 1,813
Interest expense (14,341) (18,003)
Other expense, net (27,709) (27,455)
Loss before benefit from income taxes (122,895) (112,334)
Benefit from income taxes 62 46,180
Losses from equity method investments (3,086) (1,883)
Net Loss $ (125,919) $ (68,037)
Net loss per share, basic $ (0.7) $ (0.4)
Net loss per share, diluted $ (0.71) $ (0.4)
Weighted-average shares outstanding used to compute net loss per share, basic 178,880 170,506
Weighted-average shares outstanding used to compute net loss per share, diluted 178,964 170,506
Comprehensive Loss, net of tax    
Net loss $ (125,919) $ (68,037)
Foreign currency translation adjustment (1,810) 4,598
Comprehensive loss (127,729) (63,439)
Diagnostics [Member]    
Net revenue    
Total net revenue 261,098 193,804
Cost and operating expenses    
Cost of revenues 100,960 84,783
Data and applications [Member]    
Net revenue    
Total net revenue [1] 87,018 61,933
Cost and operating expenses    
Cost of revenues $ 25,115 $ 15,751
[1] Includes related party revenue of $21,823 and $631 for the three months ended March 31, 2026 and 2025, respectively.